We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).
- Authors
Jung, Eun Hee; Byun, Ja Min; Shin, Dong‐Yeop; Do, Young Rok; Jo, Jae‐Cheol; Lee, Sang Min; Yoon, Sung‐Soo
- Abstract
Background: Current guidelines recommend using filgrastim or tbo‐filgrastim to mobilize hematopoietic progenitor cells in an autologous setting. However, previous studies have suggested other forms of granulocyte colony‐stimulating factor (G‐CSF) are equally efficacious, possibly with fewer leukaphereses required. Thus, we prospectively studied the efficacy of lenograstim, a glycosylated recombinant form of G‐CSF, in multiple myeloma (MM) patients. Methods: From November 2011 to January 2020, 98 MM patients undergoing autologous stem cell transplant (ASCT) from five academic centers in Korea were enrolled. Patients were mobilized with subcutaneous lenograstim (Neutrogin®) with fixed doses of 10 μg/kg for 4 days. Results: Most of the patients (N = 90, 91.8%) achieved at least the targets of 2 × 106 CD34+ cells/kg body weight, and more than half of MM patients (N = 57, 58.2%) reached a target of 5 × 106 CD34+ cells/kg body weight. The mobilization failure rate was 8.2% (N = 8). The median number of CD34 + cell/kg using G‐CSF only was 5.25 × 106/kg (range 0.49–13.47). Adverse events included transfusion (TF, N = 53, 54.1%), bone pain (N = 6, 6.1%), fever (N = 2, 2.0%), and gastrointestinal troubles (N = 2, 2.0%). There were no grade 3 or 4 adverse events during mobilization. Body surface area (BSA) at mobilization and platelet TF were factors associated with CD34+ collection. Most patients achieved neutrophil (N = 93, 98.9%) and platelet (N = 89, 95.7%) engraftment. Conclusion: Lenograstim can safely and effectively mobilize stem cells in MM autologous settings.
- Subjects
SOUTH Korea; HEMATOPOIETIC stem cells; MULTIPLE myeloma; GRANULOCYTE-colony stimulating factor; STEM cell transplantation; BODY surface area
- Publication
Cancer Medicine, 2023, Vol 12, Issue 8, p9186
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.5657